Compounded Semaglutide Side Effects and Safety: A Clinical Reference

Published Jun 2, 2026Updated Jun 2, 2026Last reviewed Jun 2, 2026

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last updated: May 2026

Lisa, a 46-year-old nurse practitioner in Charlotte, was three weeks into her semaglutide titration when she called her prescribing clinic in a low-grade panic. "I threw up twice after dinner, and now my lower back is killing me," she told the intake coordinator. "I Googled 'semaglutide pancreatitis' and I'm pretty sure I'm dying." She wasn't dying. A quick phone consult established that the pain was muscular (she'd helped a patient transfer that morning), and the vomiting tracked with a heavy pasta dinner she'd eaten too fast. But Lisa's fear was reasonable. She'd read a half-dozen articles about semaglutide safety, all of them either breathlessly optimistic or vaguely terrifying, and none of them had given her a framework for sorting serious warning signs from predictable nuisance symptoms. That's the gap this page is meant to fill.

The safety profile of semaglutide is one of the most extensively studied in modern endocrinology. Between the SUSTAIN program in type 2 diabetes, the STEP program in chronic weight management, and the SELECT cardiovascular outcomes trial, the molecule has been studied in tens of thousands of patients over treatment durations exceeding two years. The adverse event data is detailed, consistent across trials, and broadly reassuring. But "broadly reassuring" is not the same thing as "nothing to worry about." Semaglutide is a potent drug with real biological effects, and the side effect profile reflects that.

This page is a clinical reference for what the data actually show. It's written for patients considering compounded semaglutide, for patients already on therapy who want context for symptoms they're experiencing, and for clinicians looking for a plain-language summary they can share. Compounded semaglutide is not FDA-approved, and the safety data discussed here comes from trials of the FDA-approved branded products that share semaglutide as the active ingredient. The pharmacological behavior of the active ingredient is the same. The compounded preparation is patient-specific and dispensed under an individual prescription.

For background on what compounded semaglutide is and the regulatory framework, see the pillar guide.

Four Categories, Not One Blurry List

The single most useful thing you can do when thinking about semaglutide side effects is stop treating them as one category. They're not. Lumping nausea together with thyroid cancer risk is like grouping a paper cut with a car accident because both involve injury. Clinically, semaglutide adverse events break into four distinct buckets:

Gastrointestinal effects (common, usually transient, manageable)
Metabolic effects (context-dependent, mainly relevant to diabetic patients on combination therapy)
Structural and organ-system risks (uncommon but clinically significant when they occur)
Theoretical concerns (raised in regulatory and academic discussions but without established causal evidence)

Separating these is the first step toward knowing which symptoms require an urgent call to your clinic and which ones mean you ate too much fettuccine.

The GI Reality: Common, Predictable, and Usually Temporary

GI side effects are the main event. They account for almost all therapy discontinuations, and they're the reason most patients (like Lisa) end up anxious during the first month.

In STEP-1 (Wilding et al., NEJM 2021), 74.2 percent of patients on semaglutide 2.4 mg reported at least one GI adverse event during the 68-week trial, compared to 47.9 percent on placebo. The specific numbers:

Nausea: 44.2 percent on semaglutide versus 16.1 percent on placebo
Diarrhea: 31.5 percent versus 15.9 percent
Vomiting: 24.8 percent versus 6.6 percent
Constipation: 23.4 percent versus 9.5 percent

Those numbers look alarming until you read the fine print. These events were mostly mild to moderate and concentrated in the early weeks of titration. Most patients reported that symptoms resolved within a few days of each dose escalation. About 7 percent of semaglutide patients in STEP-1 discontinued the drug due to GI adverse events, meaning the other 93 percent found the symptoms tolerable enough to continue.

Here's the thing about the biological mechanism: slow gastric emptying is part of how semaglutide suppresses appetite. You can't eliminate the GI effects without losing the therapeutic effect. It's a feature and a bug simultaneously, like how antihistamines make you drowsy because the pathway that stops your sneezing also crosses into your sleep architecture.

The management framework is unglamorous but effective. Eat smaller meals. Stop eating before you feel full (this is harder than it sounds for most people). Avoid high-fat, greasy foods, which delay gastric emptying further. Limit alcohol. Stay hydrated, particularly if you have diarrhea or vomiting, because dehydration is the single most common cause of acute kidney complications on GLP-1 therapy. If symptoms are severe enough that you cannot maintain oral hydration, contact your prescribing clinic before continuing therapy. Do not tough it out.

For specific symptom management, see our supporting article on managing semaglutide nausea.

Hypoglycemia: Mostly a Non-Issue, With One Big Exception

Semaglutide is not a hypoglycemia-inducing drug when used alone in patients without diabetes. This is one of the things that makes GLP-1 receptor agonists fundamentally different from older diabetes drugs. They have a glucose-dependent insulinotropic effect, meaning they stimulate insulin release in response to elevated blood glucose but do not push insulin out at normal or low glucose levels. It's an elegant mechanism.

The exception matters, though. In patients with type 2 diabetes who are taking semaglutide alongside insulin or a sulfonylurea, hypoglycemia risk increases substantially. This is a drug-interaction problem, not a semaglutide problem per se, and the standard clinical response is to reduce the dose of the concurrent diabetes medication. Patients in this situation need coordinated care between the semaglutide prescriber and the diabetes care team. If those two providers aren't talking to each other, that's a red flag.

In non-diabetic patients, reports of low blood sugar symptoms typically reflect under-eating, alcohol consumption on an empty stomach, or a viral illness rather than true biochemical hypoglycemia. If you're feeling shaky and lightheaded, check your glucose with a meter if you have one and contact your clinic.

The Serious Stuff: Pancreatitis, Gallbladder, Kidneys, and Surgery

These risks are uncommon, but they're the ones that matter most when they show up.

Pancreatitis is included in the Wegovy and Ozempic labels as a precaution. The clinical trial data do not establish a clear causal increase in pancreatitis rates compared to placebo, but post-marketing reports prompted regulators to require monitoring. Acute pancreatitis presents as severe, persistent abdominal pain that radiates to the back, often with vomiting. This is not garden-variety nausea. This is pain bad enough that you know something is wrong. Any patient on semaglutide with these symptoms should stop the drug and seek immediate evaluation. Semaglutide should not be restarted after a confirmed pancreatitis episode without specialist evaluation.

Gallbladder disease, including cholelithiasis and cholecystitis, is more common on semaglutide than on placebo. In STEP-1, cholelithiasis was reported in 2.6 percent of semaglutide patients versus 1.2 percent on placebo. The mechanism is thought to relate to rapid weight loss (which is independently associated with gallstone formation) rather than a direct drug effect on the gallbladder. Think of it this way: anyone who loses 40 pounds in eight months faces elevated gallstone risk, whether they did it with semaglutide, bariatric surgery, or a very aggressive calorie deficit. Patients with a history of gallstones should discuss this with their prescribing clinician before starting.

Acute kidney injury has been reported on GLP-1 therapy and is almost always a downstream consequence of dehydration from severe GI symptoms. The kidneys are not a direct semaglutide target. The clinical pattern is a patient who has been vomiting for days, hasn't kept fluids down, and shows up dehydrated. Prevention is hydration. Full stop. If you cannot keep fluids down, call your clinic.

Surgical and anesthesia considerations are a newer area of attention. The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 therapy hold the medication before elective surgery due to concerns about residual gastric contents under anesthesia (the same delayed gastric emptying that suppresses appetite also means your stomach may not be empty when it needs to be). Current guidance suggests holding semaglutide for at least one week before procedures requiring general anesthesia. If you're scheduled for any surgery or procedure with anesthesia, inform both the surgical team and the prescribing clinician well in advance. Not the day before. Well in advance.

For a deeper discussion of the surgical hold protocol, see our article on semaglutide and surgery: pre-operative protocols.

The Boxed Warning Everyone Asks About

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies in which GLP-1 receptor agonists caused medullary thyroid carcinoma in rats and mice. The relevance to humans is genuinely unclear. Humans have very few C-cells in the thyroid compared to rodents, and large-scale human registries have not established a causal increase in medullary thyroid carcinoma in patients on GLP-1 therapy.

The boxed warning is nonetheless a strict contraindication for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients in these categories should not take semaglutide, period.

This is one of the screening questions any prescribing clinic should ask before initiating therapy. If you were not asked about thyroid cancer history before getting a prescription, that tells you something about the thoroughness of the clinic you're using.

Cardiovascular Safety: The Best News in the Data

The cardiovascular story is actually the strongest argument in semaglutide's favor, and it comes from the SELECT trial (Lincoff et al., NEJM 2023). SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes, and randomized them to semaglutide 2.4 mg or placebo. The primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) was reduced by 20 percent in the semaglutide arm over a mean follow-up of 39.8 months.

That's not a safety-neutral result. That's an active cardiovascular benefit, which is rare for a weight loss drug. (History is littered with weight loss medications that turned out to damage the heart. Fen-phen. Sibutramine. Semaglutide breaking that pattern is genuinely notable.)

Adverse events leading to discontinuation were more common on semaglutide (16.6 percent versus 8.2 percent on placebo), driven overwhelmingly by GI events. But serious adverse events were actually less common on semaglutide than on placebo (33.4 percent versus 36.4 percent), driven by the cardiovascular benefit.

For patients without established cardiovascular disease, SELECT doesn't directly address their specific risk-benefit calculation. But it does establish that the drug doesn't produce adverse cardiovascular signals at the maintenance dose, which, given the history of this drug class, is important information.

Emerging Concerns: What We're Watching

Several concerns have been raised in the academic and regulatory literature that don't yet have established causal evidence but are worth tracking.

Mental health and suicidal ideation. The European Medicines Agency reviewed reports of suicidal ideation in GLP-1 users in 2023 and concluded that available evidence does not support a causal link. The FDA reached a similar conclusion. Both agencies continue to monitor. My honest read: the signal is weak, the confounders are enormous (obesity itself is associated with higher rates of depression), but anyone with a history of depression or suicidal ideation should discuss this with their prescribing clinician and actively monitor mood during therapy. This is not a "probably fine, don't worry about it" situation. It's a "probably fine, but pay attention" situation.

Muscle mass loss. Rapid weight loss on semaglutide includes loss of lean body mass alongside fat mass, in proportions consistent with calorically-restricted weight loss in general. This isn't a unique semaglutide effect; it's a rapid weight loss effect. The clinical response is to maintain adequate protein intake (a common target is 1.2 to 1.6 grams of protein per kilogram of body weight per day) and to perform resistance training. See our supporting article on protecting muscle mass on semaglutide.

Hair shedding. Telogen effluvium (a temporary form of diffuse hair shedding) occurs in some patients and is well-described in the rapid weight loss literature broadly. It typically begins three to six months after the start of significant weight loss, resolves spontaneously within six to twelve months, and is not associated with permanent hair loss. It is, however, distressing, and dismissing it as "cosmetic" is unhelpful.

Vision changes. Diabetic retinopathy progression was reported in the SUSTAIN-6 trial (Marso et al., NEJM 2016) in patients with pre-existing diabetic retinopathy. The mechanism is thought to involve rapid glycemic improvement rather than a direct drug effect. Patients with diabetes and retinopathy should have an ophthalmologic evaluation before starting semaglutide.

What Your Prescriber Needs to Know

Before starting semaglutide, your prescribing clinician should know about:

A personal or family history of medullary thyroid carcinoma or MEN 2 (contraindication)
A history of pancreatitis (precaution, possibly contraindication depending on specifics)
A history of gallbladder disease
Current or recent pregnancy, or planned pregnancy within two months
All current medications, including oral medications whose absorption may change due to delayed gastric emptying
Any planned surgery or procedure requiring anesthesia within the next month
A history of eating disorders
A history of severe depression or suicidal ideation

If you're already on semaglutide, contact your clinic for:

Severe persistent abdominal pain radiating to the back
Persistent vomiting that prevents oral hydration
Signs of dehydration (dizziness, dark urine, reduced urine output)
A planned surgery or procedure
New significant mood changes or thoughts of self-harm
Vision changes
A new pregnancy or planned pregnancy

This hub is part of the Compounded Semaglutide Side Effects and Safety cluster. Related supporting articles include:

For the foundational overview, return to the pillar guide.

Frequently Asked Questions

Is Ozempic safe for weight loss? Semaglutide (the active ingredient in Ozempic and Wegovy) has been studied in tens of thousands of patients across the STEP and SELECT trial programs. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), and these are typically mild to moderate and concentrated during dose titration. Serious adverse events are uncommon. The SELECT trial showed a 20 percent reduction in major cardiovascular events. The drug is not risk-free, but the published safety data is extensive and broadly favorable.

What are the most dangerous side effects of semaglutide? The most clinically significant risks are acute pancreatitis, gallbladder disease, and acute kidney injury (almost always from dehydration). The boxed warning for thyroid C-cell tumors is based on rodent studies and has not been confirmed in human registries, but it creates a strict contraindication for patients with medullary thyroid cancer history or MEN 2.

Should I stop semaglutide before surgery? Yes. The American Society of Anesthesiologists recommends holding GLP-1 receptor agonists for at least one week before procedures requiring general anesthesia, due to concerns about delayed gastric emptying and aspiration risk. Inform your surgical team and prescribing clinician well in advance.

Does semaglutide cause hair loss? Telogen effluvium (temporary hair shedding) occurs in some patients and is associated with rapid weight loss generally, not semaglutide specifically. It typically begins three to six months after significant weight loss begins and resolves within six to twelve months without permanent hair loss.

Can semaglutide cause depression or suicidal thoughts? Both the EMA and FDA reviewed reports of suicidal ideation in GLP-1 users in 2023 and found no evidence of a causal link. Monitoring continues. Patients with a history of depression or suicidal ideation should discuss this with their prescriber and actively monitor their mood during therapy.

Does compounded semaglutide have the same side effects as Ozempic or Wegovy? Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy, so the pharmacological side effect profile is expected to be the same. Compounded semaglutide is not FDA-approved, and the safety data referenced here comes from trials of the branded products.

What should I do if I can't stop vomiting on semaglutide? Contact your prescribing clinic immediately. Persistent vomiting that prevents oral hydration is the primary risk factor for acute kidney injury on GLP-1 therapy. Do not wait it out. Dehydration is the one complication on this drug that is both preventable and potentially serious.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. References: SUSTAIN program (Marso et al., NEJM 2016), STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023).